BÁO CÁO Y HỌC: "THE HOOVER''''S SIGN OF PULMONARY DISEASE: MOLECULAR BASIS AND CLINICAL RELEVANCE" DOCX
Tìm thấy 10,000 tài liệu liên quan tới tiêu đề "BÁO CÁO Y HỌC: "THE HOOVER''''S SIGN OF PULMONARY DISEASE: MOLECULAR BASIS AND CLINICAL RELEVANCE" D...":
randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140(5):346-55. 27. Scheuer PJ, Ashrafzadeh P, Sherlock S, et al. The pathology of hepatitis C. Hepatology 1992;15(4):567-71. 28. Sheth SG, Flamm SL, Gordon FD, et al. AST/ALT ratio predicts cirrhosis in patients wi[r]
20. Hwang SJ, Luo JC, Chu CW, et al. Hepatic steatosis in chronic hepatitis C virus infection: Prevalence and clinical correlation. J Gastroenterol Hepatol 2001;16:190-5. 21. Lonardo A, Adinolfi LE, Loria P, et al. Steatopsis and hepatitis C virus: Mechanisms and significance for hepatic and extrahe[r]
treatment, but relapse occurs frequently once treatment is discontinued.[70] Other frequent extrahepatic manifestations found in patient with chronic HCV infection are membranoproliferative glomerulonephritis, porphyria cutaneous tarda, lichen planus, and vitiligo. There is also some data that sugge[r]
acceptable participation rate as well as less selection bias. We have chosen to report from the youngest age cohort participating in “The Prospective Population Study of Women in Gothenburg” as this was the age group in which lung function status was most thoroughly examined and selection bias due t[r]
4. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435-1440. 5. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, Urushihara A, Ki[r]
non-responders to peginterferon alpha 2b and ribavirin. In: AASLD (Abstract 413); Oct 29- Nov 2 2004; Boston, MA. 36. Gross JB et al. Renew Trial- High dose re-treatment with peginterferon alpha 2b plus ribavirin for non responders in chronic HCV patients. In: AASLD 2003 (Abstract 321); Oct 24-28 20[r]
and basal core promoter mutations on viral replicative interference. Hepatology 2001;34:404-410. 41. Crespo J, Lozano JL, Carte B, de las Heras B, de la Cruz F, Pons-Romero F. Viral replication in patients with concomitant hepatitis B and C virus infections. Eur J Clin Microbiol Infect Dis 1997;16:4[r]
as assessed by an HCV RNA assay with a lower limit of detection of 50 IU/ml or less 24 weeks after the end of treatment [18]. Initiation of therapy Only patients with detectable HCV RNA should be considered for pegylated IFN alfa and ribavirin combination therapy [18]. The decision to treat patients[r]
4. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435-1440. 5. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, Urushihara A, Ki[r]
antibodies [29]. Int. J. Med. Sci. 2006, 3 31Figure 2. Comparison of different replicon systems. A selection of different bicistronic and monocistronic replicon constructs including subgenomic and full-length HCV sequences is depicted schematically. Stably replicating systems are equipped among othe[r]
Int. J. Med. Sci. 2006, 3 1114. Skogsberg J, Kannisto R, Roshani L, Gagne E, Hamsten A, Larsson C, Ehrenborg E. Characterization of the human peroxisome proliferator activated receptor delta gene and its expression. Int J Mol Med. 2000; 6: 73-81. 5. Olivier WR, Shenk JL, Snaith MR, Russell CS, Plunk[r]
Rice-fluid was proved to be devoid of bactericidal activity against 5 strains of E. coli, S. aureus, S. epidermidis, E. faecalis and P. aeruginosa, and 3 strains of K. pneumoniae and 2 strains of K. oxytoca, respectively. The representative case of E. coli E1 isolate was shown in Fig.[r]
Approximately, 20 mg were homogenized using a polytron homogenizer (Tissue Tearor, BioSpec Products, Inc., Bartlesville, OK) in a mono-phase solution of phenol and guanidine thiocyanate (TRI-Reagent, Molecular Research Center, Cincinnati, OH). Total RNA was extracted per manufacturer’s instru[r]
6. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, de Jong PE. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004; 65(4):1416–1421. 7. Shimizu-Tokiwa A, Kobata M, Io H, Kobayashi N, Shou I, Funa[r]
Genetics: A Laboratory Manual. New York: Wiley Liss Inc. 1991: 519-560 7. Singer K, Chernoff Al, Singer L. Studies on abnormal hemoglobins: their demonstration in sickle cell anemia and other hematologic disorders by means of alkali denaturation. Blood.1951; 6:413-428 8. Carrell RW, Kay R. A simple[r]
each county. These systems include information on WHO’s Anatomical Therapeutic Chemical (ATC) classification code, the amount of the drug prescribed, the personal identification number, and the date of drug dispension. Since January 1 1989 all data from North Jutland County have been stored i[r]
Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-62 3. Perez CM, Suarez E, Torres EA, Roman K, Colon V. Seroprevalence of hepatitis C virus and associated risk behaviours: a population-based study in S[r]
association between maternal use of loratadine in early pregnancy and birth of infants with hypospadias was the result of multiple testing. Acknowledgments The study was supported by a grant from K A Wallenberg Foundation, Sweden, to BK. Conflict of interest The authors have declared that no conflic[r]